StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO)

StockNews.com started coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report report published on Saturday morning. The firm issued a hold rating on the biotechnology company’s stock.

APTO has been the topic of a number of other research reports. Canaccord Genuity Group cut their price objective on shares of Aptose Biosciences from $15.00 to $6.00 and set a buy rating on the stock in a research report on Thursday, May 16th. HC Wainwright reiterated a buy rating and set a $7.00 price target on shares of Aptose Biosciences in a report on Friday, June 14th. Finally, Piper Sandler reissued an overweight rating and issued a $5.00 price objective on shares of Aptose Biosciences in a research note on Wednesday, April 3rd. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and a consensus target price of $14.83.

Aptose Biosciences Stock Performance

APTO opened at $0.74 on Friday. The stock has a 50-day moving average of $1.08 and a 200 day moving average of $1.63. Aptose Biosciences has a 12 month low of $0.71 and a 12 month high of $5.58. The firm has a market cap of $13.39 million, a P/E ratio of -0.12 and a beta of 1.39.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.09. On average, research analysts forecast that Aptose Biosciences will post -2.67 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Texas Capital Bank Wealth Management Services Inc acquired a new position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 12,448 shares of the biotechnology company’s stock, valued at approximately $32,000. Texas Capital Bank Wealth Management Services Inc owned approximately 0.16% of Aptose Biosciences as of its most recent SEC filing. 26.62% of the stock is owned by institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.